GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting
GlycoMimetics (NASDAQ: GLYC) announced that multiple clinical trial data studying uproleselan in acute myeloid leukemia (AML) patients will be presented at the 66th ASH Annual Meeting in San Diego, December 7-10, 2024. The presentations include: an international Phase 3 trial comparing uproleselan plus chemotherapy versus chemotherapy alone in relapsed/refractory AML; updated results from a Phase I study combining uproleselan with azacitidine and venetoclax in older/unfit treatment-naive AML patients; and final results of a Phase II study of uproleselan combined with cladribine and low-dose cytarabine for treated secondary AML.
GlycoMimetics (NASDAQ: GLYC) ha annunciato che più dati da studi clinici su uproleselan in pazienti con leucemia mieloide acuta (LMA) saranno presentati al 66° Congresso Annuale ASH a San Diego, dal 7 al 10 dicembre 2024. Le presentazioni includono: uno studio internazionale di Fase 3 che confronta uproleselan più chemioterapia rispetto alla chemioterapia da sola nei pazienti con LMA relapsata/rifrangente; risultati aggiornati da uno studio di Fase I che combina uproleselan con azacitidina e venetoclax in pazienti anziani o non idonei non trattati con LMA; e i risultati finali di uno studio di Fase II di uproleselan combinato con cladribina e citarabina a basse dosi per LMA secondaria trattata.
GlycoMimetics (NASDAQ: GLYC) anunció que se presentarán múltiples datos de ensayos clínicos que estudian uproleselan en pacientes con leucemia mieloide aguda (LMA) en la 66ª Reunión Anual de ASH en San Diego, del 7 al 10 de diciembre de 2024. Las presentaciones incluyen: un ensayo internacional de Fase 3 que compara uproleselan más quimioterapia frente a solo quimioterapia en LMA en recaída/refractaria; resultados actualizados de un estudio de Fase I que combina uproleselan con azacitidina y venetoclax en pacientes ancianos/no aptos no tratados con LMA; y resultados finales de un estudio de Fase II de uproleselan combinado con cladribina y citarabina a baja dosis para LMA secundaria tratada.
GlycoMimetics (NASDAQ: GLYC)는 급성 골수 백혈병(AML) 환자에서 업롤레살란에 대한 여러 임상 시험 데이터를 2024년 12월 7일부터 10일까지 샌디에이고에서 열리는 제66회 ASH 연례 회의에서 발표할 것이라고 발표했습니다. 발표 내용에는 재발/불응성 AML에서 화학요법 단독 대 화학요법과 업롤레살란 병용 요법을 비교하는 국제 3상 시험, 노인/부적합한 치료받지 않은 AML 환자에서 업롤레살란과 아자시티딘 및 베네토클락스를 병용한 1상 연구의 업데이트된 결과, 치료받은 이차 AML에 대해 업롤레살란을 클라드리빈 및 저용량 시타라빈과 결합한 2상 연구의 최종 결과가 포함됩니다.
GlycoMimetics (NASDAQ: GLYC) a annoncé que plusieurs données d'essais cliniques étudiant uproleselan chez des patients atteints de leucémie myéloïde aiguë (LMA) seront présentées lors de la 66e Réunion Annuelle de l'ASH à San Diego, du 7 au 10 décembre 2024. Les présentations incluent : un essai international de phase 3 comparant uproleselan plus chimiothérapie contre chimiothérapie seule chez des patients AML en rechute/réfractaires ; des résultats mis à jour d'une étude de phase I combinant uproleselan avec azacitidine et venetoclax chez des patients âgés/non aptes n'ayant jamais été traités pour AML ; et les résultats finaux d'une étude de phase II d'uproleselan combiné avec cladribine et cytarabine à faible dose pour une AML secondaire traitée.
GlycoMimetics (NASDAQ: GLYC) hat bekannt gegeben, dass mehrere klinische Studiendaten zu uproleselan bei Patienten mit akuter myeloischer Leukämie (AML) auf dem 66. ASH-Jahrestreffen in San Diego vom 7. bis 10. Dezember 2024 präsentiert werden. Die Präsentationen umfassen: eine internationale Phase-3-Studie, die uproleselan plus Chemotherapie mit Chemotherapie allein bei rezidivierter/refraktärer AML vergleicht; aktualisierte Ergebnisse einer Phase-I-Studie, die uproleselan mit Azacitidin und Venetoclax bei älteren/ungeeigneten therapienaiven AML-Patienten kombiniert; sowie die finalen Ergebnisse einer Phase-II-Studie von uproleselan in Kombination mit Cladribin und Niedrigdosis-Cytarabin für behandelte sekundäre AML.
- Multiple clinical trial data presentations at a major industry conference (ASH)
- Phase 3 trial results to be presented for uproleselan in AML
- Diverse clinical program with three different studies across various phases
- None.
ASH Annual Meeting abstracts may be accessed online at www.hematology.org. Details of GlycoMimetics presentations are as follows (all times PT):
Publication Number: 733
Type: Oral
Title: Efficacy and Safety of Uproleselan Combined with Chemotherapy Vs. Chemotherapy Alone in Relapsed/Refractory Acute Myeloid Leukemia: Findings from an International Phase 3 Trial
Presenter: Daniel DeAngelo, M.D., Ph.D.
Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML
Session Date/ Presentation Time: Monday, December 9, 2024, 10:30 AM – 12:00 PM
Publication Number: 1503
Type: Poster
Title: Updated Results of a Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naive Acute Myeloid Leukemia
Presenter: Brian Jonas, M.D., Ph.D.
Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster I
Session Date/ Presentation Time: Saturday, December 7, 2024, 5:30 PM - 7:30 PM
Publication Number: 4262
Type: Poster
Title: Final Results of a Phase II Study of Uproleselan Combined with Cladribine and Low-Dose Cytarabine for Patients with Treated Secondary Acute Myeloid Leukemia (ts-AML)
Presenter: Caitlin Rausch, PharmD.
Session Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III
Session Date/Presentation Time: Monday, December 9, 2024, 6:00 – 8:00 PM
About GlycoMimetics, Inc.
GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform can be used to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in
Forward-Looking Statements
To the extent that statements contained herein are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. (“GlycoMimetics,” “we,” “us,” or “our”). Forward-looking statements include, but are not limited to, the expected presentation of clinical data for uproleselan, and any other statement containing terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “intends,” or “continue,” or the negative of these terms or other comparable terminology. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those discussed, implied or otherwise anticipated by such statements. You are cautioned not to place undue reliance on such forward-looking statements, which are current only as of the date of this presentation. For a further description of the risks associated with forward-looking statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241106949513/en/
Investors:
Argot Partners
212-600-1902
Glycomimetics@argotpartners.com
Source: GlycoMimetics, Inc.
FAQ
When will GlycoMimetics (GLYC) present its uproleselan clinical data at ASH 2024?
What types of clinical trials for uproleselan will GLYC present at ASH 2024?
What is the focus of GLYC's Phase 3 trial presentation at ASH 2024?
